Find information on thousands of medical conditions and prescription drugs.

Fluocinonide

Fluocinonide (a corticosteroid) constitute a class of primatily synthetic steroids used topically as an anti-inflamatory and anti-pruritic agents. more...

 Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

<chemical> 6α,9-difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone,21-acetate. A topical glucocorticoid used in the treatment of eczemas.

Pharmacological action: anti-allergic agents, steroidal anti-inflammatory agents, glucocorticoids, synthetic, glucocorticoids, topical.

Chemical name: Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6α, 11β, 16α) -

Molecular Formula: C26H32F2O7

Mol. Wt: 494.53

Read more at Wikipedia.org
• [List your site here Free!]

Fluocinonide 0.1% cream approved for plaque-type psoriasis
From Journal of Drugs in Dermatology, 5/1/05

Patheon Inc. announced FDA approval of Vanos[R] (fluocinonide 0.1%) cream for the treatment of plaque-type psoriasis affecting up to 10% body surface area. Vanos is a class 1 corticosteroid formulated for once or twice daily application. Approval was based on results from a double-blind, randomized clinical trial demonstrating 31% of patients achieving clearance or near-clearance of psoriatic plaques with twice daily application for 2 weeks.

The most commonly reported adverse events noted were burning sensations at application sites and headache. Hypothalamic-pituitary-adrenal axis suppression was seen in 2 of 18 patients whose mean body surface area ranged from 10% to 50%. Due to the risk of HPA axis suppression, treatment with Vanos should not exceed two weeks, nor should it exceed 60 grams per week. In addition, as its safety has not been established in this population, fluocinonide cream 0.1% should not be used in patients younger than eighteen years.

COPYRIGHT 2005 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group

Return to Fluocinonide
Home Contact Resources Exchange Links ebay